1. Soluble BAFF Level Is Not Correlated to Mycobacterium avium Subspecies Paratuberculosis Antibodies and Increases After Interferon-β Therapy in Multiple Sclerosis Patients.
- Author
-
Mameli G, Cossu D, Caggiu E, Arru G, Niegowska M, Cocco E, Frau J, Marrosu MG, and Sechi LA
- Subjects
- Adult, Antibodies, Bacterial blood, Case-Control Studies, Female, Humans, Immunologic Factors adverse effects, Interferon-beta adverse effects, Male, Middle Aged, Multiple Sclerosis complications, Multiple Sclerosis drug therapy, Paratuberculosis complications, B-Cell Activating Factor blood, Immunologic Factors therapeutic use, Interferon-beta therapeutic use, Multiple Sclerosis blood, Mycobacterium avium immunology, Paratuberculosis blood
- Abstract
B cells are being recognized as one of the major players in the pathogenesis of multiple sclerosis (MS). The B cell activating factor (BAFF) system plays an essential role in B cell homeostasis and function in the periphery. Mycobacterium avium subspecies paratuberculosis (MAP) has been previously associated to MS in Sardinia. Antibodies against a MAP surface protein, MAP_2694, have been found significantly associated to MS patients, and this response was modified by interferon-β therapy. Increased BAFF levels following IFN-β therapy have been also described in MS patients. In this study, we evaluated whether soluble BAFF levels are comparable in men and women affected by MS and performed a correlation of the reported BAFF increase in MS patients under IFN-β therapy with changes of humoral response against MAP_2694. For these reasons, we investigated 44 MS patients before and after IFN-β therapy. A significant difference of BAFF levels was found between men and women with MS; moreover, we confirmed that IFN-β therapy strongly induces BAFF serum levels, but this was not related to the modification of immunological response against MAP_2694. In conclusion, our study highlights that IFN-β therapy induces the potent B cell survival factor BAFF without alterations of the humoral immune response against MAP.
- Published
- 2016
- Full Text
- View/download PDF